Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report

Author(s):  
Insook Kim ◽  
Shirley Seo
2017 ◽  
Vol 5 (1) ◽  
pp. 7-15
Author(s):  
Sanasam Sanjeev ◽  
◽  
Maibam Sunita Devi ◽  
Khushboo Maurya ◽  
Vikas Kumar Roy ◽  
...  

Diosgenin [25R-spriost-5-en-3þ-ol], is an important steroidal metabolite found in various plant species. The discovery of diosgenin has made it one of the most researched and studied herbal product. Moreover, there is excellent opportunity to address whether diosgenin plays a role in chemoprevention versus therapy, or both. However, rigorous experimental based evidence in support of ethnomedicine-derived notions would lead to the development of products relevant to drug development. The health beneficial effects of diosgenin are further extended to its potential role to treat other ailments such as HIV and hepatitis-C infections as well as liver diseases. There is little information regarding the bioavailability, pharmacokinetics and pharmacodynamics of diosgenin in relation to its health beneficial effects. It has been reported to have wide spectrum of biological properties that contributes to several diseases in its role as a health beneficial phytochemical by citing new studies.


Author(s):  
Gina Pastino ◽  
Diana Shuster

The use and acceptance of cannabis, either medically or recreationally, has substantially outpaced the collection of data necessary to evaluate its use in any population. However, the mere widespread availability does not imply the absence of risk or confirmation of efficacy and should not be treated as such. There is enough data to suggest that not only does the potential for pharmacokinetic and metabolic interactions exist, but also that baseline characteristics for a given population could be different in chronic cannabis users. Either or both of these may impact the safety and efficacy profile for any new drug in development. As such, we encourage drug developers to consider that the cannabis user may very well be a special population that warrants its own clinical pharmacology evaluation.


Author(s):  
Bilal Abuasal ◽  
Mariam A. Ahmed ◽  
Priyank Patel ◽  
Salwa Albusaysi ◽  
Sreedharan Sabarinath ◽  
...  

2021 ◽  
pp. 243-256
Author(s):  
Ann-Charlotte Egnell ◽  
Susanne Johansson ◽  
Chao Chen ◽  
Alienor Berges

2020 ◽  
Vol 108 (4) ◽  
pp. 710-715
Author(s):  
Rajanikanth Madabushi ◽  
Elimika Pfuma Fletcher ◽  
Jeffry Florian ◽  
Lauren Milligan ◽  
Anuradha Ramamoorthy ◽  
...  

2019 ◽  
Vol 46 (5) ◽  
pp. 395-409 ◽  
Author(s):  
Mariam A. Ahmed ◽  
Malek Okour ◽  
Richard Brundage ◽  
Reena V. Kartha

2015 ◽  
Vol 49 (6) ◽  
pp. 861-868 ◽  
Author(s):  
Jian Wang ◽  
Hoi-Kei Lon ◽  
Shwu-Luan Lee ◽  
Gilbert J. Burckart ◽  
David S. Pisetsky

Sign in / Sign up

Export Citation Format

Share Document